AU2905199A - Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject - Google Patents
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subjectInfo
- Publication number
- AU2905199A AU2905199A AU29051/99A AU2905199A AU2905199A AU 2905199 A AU2905199 A AU 2905199A AU 29051/99 A AU29051/99 A AU 29051/99A AU 2905199 A AU2905199 A AU 2905199A AU 2905199 A AU2905199 A AU 2905199A
- Authority
- AU
- Australia
- Prior art keywords
- subject
- tumor cells
- chemotherapeutic agent
- oncolytic virus
- combined therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1999/005536 WO2000054795A1 (en) | 1999-03-15 | 1999-03-15 | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2905199A true AU2905199A (en) | 2000-10-04 |
Family
ID=22272350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU29051/99A Abandoned AU2905199A (en) | 1999-03-15 | 1999-03-15 | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2905199A (en) |
| WO (1) | WO2000054795A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020109389A1 (en) | 2018-11-28 | 2020-06-04 | Innovative Molecules Gmbh | Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US7470426B1 (en) | 1997-10-09 | 2008-12-30 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
| US7780962B2 (en) | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
| MXPA01010393A (en) | 1999-04-15 | 2004-04-02 | Pro Virus Inc | Treatment of neoplasms with viruses. |
| US8147822B1 (en) | 1999-09-17 | 2012-04-03 | Wellstat Biologics Corporation | Oncolytic virus |
| NO20014256D0 (en) | 2001-09-03 | 2001-09-03 | Bjoern Kristiansen | Preparation of immunostimulatory compound |
| KR20070008710A (en) * | 2004-04-27 | 2007-01-17 | 웰스테트 바이올로직스 코포레이션 | Cancer treatment method using virus and camptothecin |
| US7514085B2 (en) | 2004-07-16 | 2009-04-07 | Medimush A/S | Immune modulating compounds from fungi |
| EP1896600A2 (en) | 2005-06-15 | 2008-03-12 | Medimush A/S | Anti-cancer combination treatment and kit-of-part |
| CN102124335B (en) * | 2008-05-22 | 2014-07-30 | 第一药品株式会社 | Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy |
| CA2689707A1 (en) | 2009-11-16 | 2011-05-16 | Jean-Simon Diallo | Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening |
| ES2704848T3 (en) * | 2011-10-12 | 2019-03-20 | Sbi Pharmaceuticals Co Ltd | Treatment agent and / or prophylactic agent for side effects of cancer drugs |
| EP2662117A1 (en) * | 2012-05-11 | 2013-11-13 | Virttu Biologics Limited | Herpes Simplex Virus for the treatment of liver cancer |
| KR20230107375A (en) | 2014-12-18 | 2023-07-14 | 암젠 인크 | Stable frozen herpes simplex virus formulation |
| GB201509338D0 (en) * | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| JP2020510050A (en) | 2017-03-15 | 2020-04-02 | アムジエン・インコーポレーテツド | Use of an oncolytic virus alone or in combination with a checkpoint inhibitor to treat cancer |
| TW201900193A (en) | 2017-04-28 | 2019-01-01 | 美商默沙東藥廠 | Biomarkers for cancer treatment |
| SI3661954T1 (en) | 2017-08-03 | 2022-05-31 | Amgen Inc. | Interleukin-21 muteins and treatment procedures |
| TW201912173A (en) | 2017-08-07 | 2019-04-01 | 美商安進公司 | Treatment of triple-negative breast cancer or colorectal cancer with liver metastasis |
| ES2985118T3 (en) | 2017-09-08 | 2024-11-04 | Amgen Inc | KRAS G12C inhibitors and methods of using them |
| UY38049A (en) | 2018-01-12 | 2019-07-31 | Amgen Inc | ANTI-PD-1 ANTIBODIES AND TREATMENT METHODS |
| WO2019168346A1 (en) * | 2018-02-28 | 2019-09-06 | 주식회사 바이오녹스 | Pharmaceutical composition for preventing or treating cancer comprising anticancer virus and hydroxyurea as effective components |
| MX2021007639A (en) | 2018-12-27 | 2021-08-11 | Amgen Inc | Lyophilized virus formulations. |
| US20220090133A1 (en) | 2019-03-05 | 2022-03-24 | Amgen Inc. | Use of oncolytic viruses for the treatment of cancer |
| TW202102543A (en) | 2019-03-29 | 2021-01-16 | 美商安進公司 | Use of oncolytic viruses in the neoadjuvant therapy of cancer |
| JP7326663B2 (en) * | 2019-08-26 | 2023-08-16 | バイオノックス インコーポレイテッド | Pharmaceutical composition containing vaccinia virus and hydroxyurea as active ingredients for the treatment of cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5772993A (en) * | 1997-01-21 | 1998-06-30 | The University Of Virginia Patent Foundation | Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues |
-
1999
- 1999-03-15 AU AU29051/99A patent/AU2905199A/en not_active Abandoned
- 1999-03-15 WO PCT/US1999/005536 patent/WO2000054795A1/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020109389A1 (en) | 2018-11-28 | 2020-06-04 | Innovative Molecules Gmbh | Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000054795A1 (en) | 2000-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2905199A (en) | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject | |
| AU2001228205A1 (en) | Linac neutron therapy and imaging | |
| AU3957600A (en) | Piperidyl-imidazole derivatives, their preparations and therapeutic uses | |
| ZA979096B (en) | Viral and cancer treatment | |
| AU7459600A (en) | Smooth muscle cell promoter and uses thereof | |
| AU2736101A (en) | Transporters and ion channels | |
| PL352330A1 (en) | Derivatives of pyridopyranoazepine, making of same and use of same in therapy | |
| AU2868999A (en) | Improvements in wheeled luggage and associated devices | |
| AU715620C (en) | Therapeutic methods and uses | |
| AU9633098A (en) | Benzoxazine derivatives, preparation and application in therapy | |
| AU2002232925A1 (en) | Air-flow containment and distribution assembly | |
| AU5918098A (en) | Non-immunogenic prodrugs and selectable markers for use in gene therapy | |
| AU2452197A (en) | Genes amplified in cancer cells | |
| AU2001266229A1 (en) | Hcn polypeptides and polynucleotides and their use in therapy | |
| AU9269898A (en) | Artificial viruses derived from papillomavirus, and their uses, in particular gene therapy | |
| AU4328399A (en) | Nucleic acid-cobalamin complexes and their use in gene therapy | |
| AU2529799A (en) | Benzofuran-4-carboxamides and their therapeutic use | |
| IL133536A0 (en) | 6-pyrrolidin-2-ylpyridine derivatives, their preparation and application in therapy | |
| AU2383300A (en) | Diagonal toy pieces and their connection | |
| AU1576501A (en) | Methods to enhance and confine gene expression in cancer therapy | |
| AU5764399A (en) | Antigen-presenting cells and their use in therapy | |
| IL112992A0 (en) | Recombinant viruses, their preparation and their use in gene therapy | |
| AU4860299A (en) | (zap-3) tumor associated genes and their uses | |
| AU6924198A (en) | Benzenesulphonamide derivatives, preparation and application thereof in therapy | |
| AU6149600A (en) | Novel vector complexes and their use in gene therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |